Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLON long-term open-label erenumab safety and tolerability study in migraine
2019-002201-22Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erenumab in migraine, sponsored by Novartis. Primary endpoint: Exposure-adjusted incidence rate of adverse events during open-label treatment per 100 subject-years. Started Jun 2019; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2019-002201-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002201-22.